Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alterity TherapeuticsASX:ATH +2.83%28 3-Year Share Buyback Ratio is -55.90 as of Mar. 2026. GuruFocus rates ASX:ATH with a GF Score™ of 28/100. Among 1,196 Biotechnology companies, Alterity Therapeutics ranks worse than 85.03% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Alterity Therapeutics's current 3-Year Share Buyback Ratio was -55.90%.
The historical rank and industry rank for Alterity Therapeutics's 3-Year Share Buyback Ratio or its related term are showing as below:
ASX:ATH'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -144.7 Med: -21.3 Max: 0
Current: -55.9
During the past 13 years, Alterity Therapeutics's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was -144.70%. And the median was -21.30%.
ASX:ATH's 3-Year Share Buyback Ratio is ranked worse than 85.03% of 1196
companies
in the Biotechnology industry
Industry Median: -11.65
vs ASX:ATH: -55.90
Alterity Therapeutics (ASX:ATH) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Alterity Therapeutics 3-Year Share Buyback Ratio Related Terms
ASX:ATH vs VRTX, REGN, RVMD: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Alterity Therapeutics's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alterity Therapeutics 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Alterity Therapeutics's 3-Year Share Buyback Ratio falls into.
Alterity Therapeutics 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -55.90 mean?
Alterity Therapeutics (ASX:ATH) has a 3-Year Share Buyback Ratio of -55.90 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Alterity Therapeutics and its competitors. According to the industry distribution chart, Alterity Therapeutics ranks #1017 out of 1196 companies in the Biotechnology industry, placing it in the top 85%.
Is Alterity Therapeutics' 3-Year Share Buyback Ratio too high?
Alterity Therapeutics' current 3-Year Share Buyback Ratio is -55.90. Based on the distribution chart, Alterity Therapeutics ranks #1017 out of 1196 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alterity Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alterity Therapeutics ranks #1017 out of 1196 companies for 3-Year Share Buyback Ratio. This places Alterity Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Alterity Therapeutics and its competitors. Alterity Therapeutics's current 3-Year Share Buyback Ratio is -55.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current 3-Year Share Buyback Ratio of -55.90. The current 3-Year Share Buyback Ratio is -55.90. Alterity Therapeutics' overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current 3-Year Share Buyback Ratio is -55.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
28GF Score
Get the complete analysis for ASX:ATH
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ATH has been successfully added to your 
